Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2018-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85dcbb4bc4c551c3fa43caf48768f917 |
publicationDate |
2020-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2018333106-A1 |
titleOfInvention |
Use of il-1b binding antibodies for the treatment of alcoholic hepatitis |
abstract |
The present invention relates to a method for treating or alleviating the symptoms of alcoholic hepatitis in a subject, comprising administering gevokizumab or 2-5 mg of canakinumab per kg of body weight to a subject in need thereof. |
priorityDate |
2017-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |